Atrial Fibrillation: Clinical Breakdown: Electrophysiology, Classification Patterns, Etiology, Thromboembolic Risk, and Comprehensive Therapeutic Management
A cardiology pathology reference on the ECG signature of AFib, paroxysmal, persistent and permanent classification, pulmonary vein ectopy and re-entry, atrial remodeling, and the combination of stroke risk stratification with rate or rhythm control.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is the strongest of the four briefs. The electrophysiology is accurate, the classification is correct, and the core clinical principle, that loss of atrial contraction causes stasis in the left atrial appendage and thromboembolic risk, is both right and correctly identified as the thing that matters most.
- The classification table is accurate. Paroxysmal AFib self-terminates within seven days, persistent lasts beyond seven days and requires intervention, and permanent reflects an accepted rhythm rather than a technical impossibility. The brief handles that last distinction well, which many references get wrong by implying permanent means unconvertible.
- One category is missing: long-standing persistent AFib, meaning continuous AFib for more than a year where a rhythm-control strategy is still being pursued. It matters because it is the group where ablation success rates fall most sharply, so it changes what is offered.
- The pulmonary vein ectopy section is correct and would benefit from the clinical consequence being stated: because the triggers are concentrated in the muscular sleeves at the pulmonary vein ostia, pulmonary vein isolation is the standard ablation target. The mechanism and the procedure should be connected explicitly, since that connection is the whole basis of modern ablation.
- The AV node is not mentioned anywhere, and it should be. The node's variable filtering of 300 to 600 atrial impulses per minute is what produces the irregularly irregular ventricular response, what keeps the rhythm survivable, and what rate-control agents actually act on. Without it, the brief describes atrial chaos but never explains the pulse.
- On therapeutic strategy, the brief lists CHA2DS2-VASc scoring with anticoagulation alongside rate or rhythm control, which is the correct structure. Two points should be added. First, DOACs are first-line for most patients, with warfarin reserved for mechanical valves and moderate to severe rheumatic mitral stenosis. Second, antiplatelet therapy is not an adequate substitute for anticoagulation in patients who meet the threshold, a point that still needs making.
- Bleeding risk assessment is absent. It belongs beside the stroke score, with the important caveat that a high bleeding score is primarily a prompt to correct modifiable factors, uncontrolled hypertension, alcohol, avoidable NSAIDs, labile INR, rather than a reason to withhold anticoagulation.
- The antiarrhythmic list is appropriately brief, and the safety constraints that govern the choice are not stated. Flecainide and propafenone are contraindicated in significant structural or coronary disease, and amiodarone carries thyroid, pulmonary, hepatic, ocular and dermatologic toxicity requiring monitoring. These restrictions are the reason drug choice is individualized.
- The rate-versus-rhythm discussion omits the most significant recent change in practice. AFFIRM in 2002 found no survival advantage to rhythm control with the drugs then available, and EAST-AFNET 4 in 2020 found benefit from early rhythm control in recently diagnosed patients. Practice has shifted, and a clinical reference written now should reflect that.
- Tachycardia-induced cardiomyopathy is not mentioned. A persistently uncontrolled ventricular rate can itself cause ventricular dysfunction, and it is substantially reversible with rate control, which makes it a practically important diagnosis to consider.
- Cardioversion timing is absent and is a genuine safety point. In AFib of more than 48 hours or unknown duration, cardioversion requires either several weeks of prior anticoagulation or transesophageal echocardiography to exclude atrial thrombus, with anticoagulation continued for at least four weeks afterwards because atrial stunning persists after electrical conversion.
Download the PDF
Our reviewed pages on this
All source documents